BIOMARKER:

EGFR mutation + PD-L1 overexpression

C3 | Sensitive

C3 | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

pembrolizumab

EGFR mutation + PD-L1 overexpression|Non Small Cell Lung Cancer|pembrolizumab

osimertinib

EGFR mutation + PD-L1 overexpression|Non Small Cell Lung Cancer|osimertinib

erlotinib

EGFR mutation + PD-L1 overexpression|Lung Adenocarcinoma|erlotinib

gefitinib

EGFR mutation + PD-L1 overexpression|Lung Adenocarcinoma|gefitinib

afatinib

EGFR mutation + PD-L1 overexpression|Lung Adenocarcinoma|afatinib

PD1 inhibitor

EGFR mutation + PD-L1 overexpression|Non Small Cell Lung Cancer|PD1 inhibitor

EGFR inhibitor

EGFR mutation + PD-L1 overexpression|Non Small Cell Lung Cancer|EGFR inhibitor

EGFR mutation + PD-L1 overexpression|Lung Adenocarcinoma|EGFR inhibitor